News - Cardio-vascular


Current filters:


Popular Filters

469 to 493 of 516 results

AstraZeneca gets EU approval for Axanum; Merck & Co files ridaforolimus with EMA


Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has received approval in…

Ariad PharmaceuticalsAstraZenecaAxanumCardio-vascularEuropeMerck & CoOncologyPharmaceuticalRegulationridaforolimus

Hypercholesterolemia therapeutics market forecast to show moderate growth


The value of the global hypercholesterolemia therapeutics - cholesterol lowerers - market was put at…

Cardio-vascularMarkets & MarketingPharmaceuticalResearch

UK’s NICE backs use of TMC’s Angiox for STEMI patients undergoing primary PCI


Following a previous positive draft guidance, the UK drugs watch dog the National Institute for Health…

AngioxCardio-vascularEuropePharmaceuticalPricingRegulationThe Medicines Company

Merck & Co gets North American and Mexican rights to vernakalant iv from Astellas


US drug giant Merck & Co (NYSE: MRK) has entered into an agreement with Japan’s Astellas Pharma…

Astellas PharmaCardio-vascularCardiome PharmaLicensingMerck & CoNorth AmericaPharmaceuticalvernakalant

US FDA now joins in probe of Sanofi’s Multaq safety


The US Food and Drug Administration says it is reviewing data from a clinical trial that was evaluating…

Cardio-vascularMultaqNorth AmericaPharmaceuticalRegulationSanofi

Merck & Co sets up China marketing JV with Simcere


US pharma giant Merck & Co (NYSE: MRK) has signed a framework agreement with leading Chinese drugmaker…

Asia-PacificCardio-vascularDiabetesGenericsMarkets & MarketingMerck & CoPharmaceuticalSimcere Pharmaceutical

US FDA at last approves AstraZeneca blood-thinning drug Brilinta


There was much awaited good news for Anglo-Swedish drug major AstraZeneca (LSE: AZN) last night, when…

AstraZenecaBrilintaCardio-vascularNorth AmericaPharmaceuticalRegulation

Daiichi Sankyo debuts Lixiana in Japan for VTE prevention after orthopedic surgery


Building on its cardiovascular portfolio, Japanese drug major Daiichi Sankyo (TYO: 4568) has launched…

Asia-PacificCardio-vascularEisaiLixianaMarkets & MarketingPharmaceutical

Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq


French drug major Sanofi (Euronext: SAN) and its US biotech subsidiary Genzyme have announced mixed top-line…


Pfizer gains six months patent life for Lipitor on pediatric data; Bayer Yasmin patent scotched


US drugs behemoth Pfizer (NYSE: PFE) could extend the European patent term for its al-time blockbuster…


CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns


In two clinical disappointments announced yesterday, French drug major Sanofi (Euronext: SAN) and Germany’s…

Cardio-vascularIdera PharmaceuticalsMerck KGaAMultaqOncologyPharmaceuticalResearchSanofi

US FDA approves Bayer and J&J’s Xarelto to help prevent DVT following hip/knee replacement surgery


German drug major Bayer (BAY: DE) and US marketing partner Janssen Pharmaceuticals, a unit of Johnson…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Teva sold generic Lipitor in UK, despite ongoing patent proection, FT reports


Despite the fact that US drugs behemoth Pfizer (NYSE: PFE) has patent protection for its blockbuster…

Cardio-vascularEuropeGenericsLipitorMarkets & MarketingPatentsPfizerTeva Pharmaceutical Industries

Pfizer and ChemRar plan to explore innovative R&D partnership in Russia


Following in the footsteps of Switzerland’s Roche, global drugs behemoth Pfizer (NYSE: PFE) has…

Cardio-vascularChemRar Hi-TechOncologyPfizerPharmaceuticalResearch

AstraZeneca gets UK NICE backing for Brilique; collaborates with PTC for oncology and other potential drugs


There was good news this morning for Anglo-Swedish drug major AstraZeneca (LSE: AZN), when the UK’s…

AstraZenecaBrilintaBriliqueCardio-vascularEuropeOncologyPharmaceuticalPTC TherapeuticsRegulationResearch

Lowering LDL cholesterol does not significantly slow down CKD progression


There were some disappointing results from clinical trials for several current therapies presented at…


Pfizer and B-MS’ blood thinner Eliquis better than expected in Ph III trial


US drug majors Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) had a significant boost when they…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPradaxaResearchXarelto

Jubilant and AstraZeneca successful in delivery of early milestones in pain drug accord


Jubilant Biosys, a Bengaluru-based subsidiary of India’s Jubilant Life Sciences, and Anglo-Swedish…


AstraZeneca close to selling dental unit; fewer deaths with Brilinta in ACS patients than with clopidogrel


In a move that has been previously flagged, Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) is…

AstraZenecaBrilintaCardio-vascularMergers & AcquisitionsPharmaceuticalResearch

Positive draft guidance from UK’s NICE for GSK’s Trobalt and TMC’s Angiox


The UK’s drug watchdog body the National Institute for Health and Clinical Excellence (NICE) last…

AngioxCardio-vascularEuropeGlaxoSmithKlineNeurologicalPharmaceuticalPricingRegulationThe Medicines CompanyTrobalt

Johnson & Johnson to take $500-$600 million charge as Cordis drops Cypher heart stents


US health care giant Johnson & Johnson (NYSE: JNJ), which has suffered a steady stream of bad news relating…

Cardio-vascularFinancialJohnson & JohnsonPharmaceutical

US FDA curbs use of high-dose simvastatin, citing increased risk of muscle injury


The US Food and Drug Administration yesterday announced safety label changes for the cholesterol-lowering…

Abbott LaboratoriesCardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationSimcorSimvastatinZocor

469 to 493 of 516 results

Company Spotlight



Back to top